Replies to post #452011 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

1. It will indirectly shorten time to prove automated DCVax-l production equivalent to manual. Good for originating company and patients.

2. Once IP protections are expired (Aka: patents, exclusive use) it will make it easier/faster for generics/biosimilars to encroach on originating Company profits and reduce biological product prices. Good for biosimilar companies and patients.

3. It will create a biological state of the art arms race, wherein the original company will keep developing better, faster and more cost effective manufacturing to stay one step ahead of competition economics. Good for originating company and patients.

4. It will drive companies like NWBO to speed up Direct development once/if L is approved, in order to move toward new IP protections which biosimilars will not be able to compete against until about 2035. Good for originating company and patients.

Note: not everything here is rosy for patients, because big pharma tends to roll out new/better treatments after the prior treatment has lost IP protection. It is a given for most companies, and a flaw in the system.